CZT Cozart

Cozart PLC
09 July 2007


                                   Cozart plc

          Consortium of police forces award contract for hair testing

       Further expansion of presence in the workplace drug testing market

Abingdon, Oxfordshire, 9th July 2007 - Cozart plc ('Cozart' or the 'Company'),
the medical diagnostics company, announces that it has been awarded a contract
with a consortium of 11 regional police forces, lead by West Midlands Police
Authority, for the provision of drug testing services using hair samples.

The contract start date is 1st August 2007 for a period of 1 year with the
option to extend for a further 2 periods of 12 months each. The contract is to
provide hair testing services, including an on-site collection service, to
various police forces in England for pre-employment testing. The hair samples
will be analysed using Cozart drugs of abuse microplate elisa kits and the
sophisticated techniques of GC/MS, GC/MS/MS and LC/MS/MS at Cozart's
state-of-the-art analytical laboratories in Abingdon, Oxfordshire, for the
presence of amphetamines (including ecstasy), cannabis, cocaine, opiates, and
benzodiazepines.

This contract win follows the acquisition of Nemesis Scientific in March 2007
which expanded Cozart's position in the rapidly developing workplace market and
provided the Group with a strong workplace service offering, including an
established collection network within the UK and internationally

Dr. Chris Hand, Chief Executive of Cozart, said:

"We are delighted that the consortium of police forces led by West Midlands
Police Authority has chosen Cozart as their preferred supplier in the provision
of pre-employment hair testing.

"This contract win highlights the significant opportunities being generated from
the combination of Nemesis Scientific's workplace service offering and Cozart's
leading-edge technology position in drugs of abuse testing."


Enquiries:

Cozart plc:
Tel: 01235 861 483
Dr Chris Hand, Chief Executive
Chris Yates, Finance Director
www.cozartgroup.com

Financial Dynamics:
Tel:  020 7269 7242
Ben Atwell
Anna Keeble


Notes to editors - Cozart plc:

Cozart is a medical diagnostics company which develops, manufactures and sells
immunodiagnostic tests, predominantly those used for the detection of drugs of
abuse. Cozart's products and services include laboratory based testing kits for
the detection of drugs in a variety of biological samples, analytical laboratory
testing services and the Cozart(R) RapiScan and Cozart(R) DDS systems, portable
devices used for the on-site testing of drugs of abuse in saliva (oral fluid)
samples. In July 2004 Cozart floated on London's AIM (trading symbol: CZT).
Cozart has wholly owned subsidiaries in Spain (Spinreact SA based near
Barcelona); Sweden (HL Scandinavia and Medib Scandinavian), Italy (Cozart
Italia) and the UK (Nemesis Scientific Limited).

Cozart supplies point of contact testing products, laboratory services and
forensic testing kits to the criminal justice (e.g. police forces, probation
services and prisons), medical (e.g. hospitals and drug dependency clinics) and
workplace markets (e.g. pre-employment, random and 'for cause' testing) both in
the UK and internationally.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
NRABSGDRUGGGGRL

Cozart (LSE:CZT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Cozart (LSE:CZT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024